Company Profile
Zentalis Stock Price, News & Analysis
- Ticker:
- ZNTL
- Exchange:
- NASDAQ
- Sector:
- Small Molecule Drugs
- Location:
- United States
Stock performance
4.51 USD (+4.16%)
Close
Last updated: July 27, 2026
281M USD
Market cap
Why the stock is moving
As of Jul 27, 2026, ZNTL closed up 4.16% at $4.51. No new same-company headline was identified in the current news window.
Company overview
Business overview
Zentalis Pharmaceuticals is an oncology company with programs across solid tumors and hematologic malignancies. Its strategy centers on targeted therapies and clinical-stage differentiation.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Zentalis sits in oncology biotechnology.
Business Model Characteristics
The business depends on clinical readouts, tolerability, and the ability to advance a targeted cancer pipeline.
Position Within the Biotechnology Landscape
Zentalis is a high-beta oncology stock whose valuation is very sensitive to data quality and development execution.
Future catalysts
Zentalis's catalysts are azenosertib and the WEE1-inhibition platform, with the next oncology update deciding whether the reset has produced a cleaner story. The company still needs more proof.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK
GSK · Source: GSK plc
- 02
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
LEGN · Source: Legend Biotech Corporation
- 03
- 04
- 05
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
KYMR · Source: Kymera
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Zentalis (ZNTL)?
Zentalis (ZNTL) most recently closed at 4.51 USD, a +4.16% move versus the previous session.
What is the market cap of Zentalis (ZNTL)?
Zentalis currently has a market capitalization of 281M USD on BioPharmSignal.
What does Zentalis do?
Zentalis Pharmaceuticals is an oncology company with programs across solid tumors and hematologic malignancies. Its strategy centers on targeted therapies and clinical-stage differentiation.
On which exchange is ZNTL stock listed?
Zentalis (ZNTL) is associated with NASDAQ, United States, Small Molecule Drugs.
What is azenosertib?
Zentalis's catalysts are azenosertib and the WEE1-inhibition platform, with the next oncology update deciding whether the reset has produced a cleaner story.
Which conditions is Zentalis targeting with azenosertib?
Zentalis is associated with oncology based on its company overview and current catalyst commentary.
How does Zentalis describe recent progress with azenosertib?
Zentalis's catalysts are azenosertib and the WEE1-inhibition platform, with the next oncology update deciding whether the reset has produced a cleaner story.
What is Zentalis?
Zentalis Pharmaceuticals is an oncology company with programs across solid tumors and hematologic malignancies.